Table 1. Patient characteristics and demographics by study groups.
| Variables | Total | Non-BC | BC | P |
| N = 356 | N = 316 (88.8%) | N = 40 (11.2%) | ||
| Age(year) | 48±10 | 48±9 | 46±10 | 0.171 |
| Gender | ||||
| Male | 304 (85.4%) | 269 (85.1%) | 35 (87.5%) | 0.689 |
| Female | 52 (14.6%) | 47 (14.9%) | 5 (12.5%) | |
| Diagnosis | ||||
| FHF* | 45(12.6%) | 40(12.7%) | 5 (12.5%) | 0.577 |
| Cirrhosis | 282(79.2%) | 250 (79.1%) | 32 (80.0%) | |
| Carcinoma | 24 (6.7%) | 22 (7.0%) | 2 (5.0%) | |
| Others | 5(1.4%) | 4(1.3%) | 1(2.5%) | |
| Child-Pugh | 0.073 | |||
| Grade A | 117 (32.9%) | 113(35.8%) | 4 (10.0%) | |
| Grade B | 142 (39.9%) | 121 (35.4%) | 21 (52.5%) | |
| Grade C | 97 (27.2%) | 82 (26.9%) | 15 (37.5%) | |
| ABO blood group | ||||
| Compatible | 306 (86.0%) | 272 (86.1%) | 34 (85.0%) | 0.854 |
| Incompatible | 50 (14.0%) | 44 (13.9%) | 6 (15.0%) | |
| MELD | 0.017 | |||
| MELD≤10 | 53 (14.9%) | 50(15.8%) | 3 (7.5%) | |
| 11≤MELD≤18 | 190 (53.4%) | 175 (55.4%) | 15 (37.5%) | |
| 18<MELD≤24 | 20 (5.6%) | 13 (4.1%) | 7 (17.5%) | |
| MELD≥25 | 93 (26.1%) | 78 (24.7%) | 15 (37.5%) | |
| Surgical factors | ||||
| WIT* (min) | 3.4±0.8 | 3.4±0.8 | 3.3±0.8 | 0.497 |
| CIT* (min) | 449±111 | 440±108 | 516±107 | <0.001 |
| Anhepatic phase (min) | 58±10 | 58±10 | 58±7 | 0.578 |
| Operation time (min) | 392±95 | 389±90 | 411±130 | 0.851 |
| Blood loss(ml) | 3371±3419 | 3288±3451 | 4023±3121 | 0.025 |
| Intravenous infusion(ml) | 5890±2852 | 5893±2881 | 5869±2646 | 0.915 |
| Blood products transfusion | ||||
| RBC(U) | 8.3±10.4 | 8.1±10.6 | 10.2±8.9 | 0.013 |
| FFP*(U) | 2.0±4.7 | 1.9±4.4 | 2.8±6.5 | 0.86 |
| PLT(U) | 0.66±0.96 | 0.66±0.95 | 0.65±1.08 | 0.735 |
| Cryo* (U) | 6.3±9.7 | 5.4±9.0 | 13.5±12.2 | <0.001 |
| Whole blood(U) | 0.40±2.07 | 0.38±2.10 | 0.55±1.92 | 0.172 |
| Cell saver(ml) | 573±1396 | 550±1391 | 754±1439 | 0.091 |
| Postoperative factors | ||||
| Immunesuppressor | ||||
| FK506+MMF | 305(85.7%) | 270(85.4%) | 35(87.5%) | 0.595 |
| CysA+MMF | 43(12.1%) | 38(12.0%) | 5(12.5%) | |
| Others | 8(2.2%) | 8(2.5%) | 0(0.0%) | |
| Steroid | 195(54.8%) | 172(48.3) | 23(6.5%) | 0.713 |
| Acute rejection | 7(2.0%) | 6(1.7%) | 1(0.3%) | 0.569 |
| Chronic rejection | 9(2.5%) | 6(1.7%) | 3(0.8%) | 0.068 |
*
FHF = fulminant hepatic failure; FFP = fresh frozen plasma; WIT = warm ischemia time; CIT = cold ischemia time; Cryo = cryoprecipitate.